Aredia Does Not Prevent Disease Progression In Smoldering Myeloma Patients
According to a recent study, the bisphosphonate Aredia reduces skeletal-related events, such as bone lesions and bone fractures, in patients with smoldering multiple myeloma; however, it does not...
View ArticleResearchers Identify Factors That May Put Multiple Myeloma Patients At Higher...
Results of a recent study indicate that a history of smoking, the use of the bisphosphonate Aredia, and five genetic variations may put multiple myeloma patients at an increased risk of developing...
View ArticleExperts Recommend Intravenous Bisphosphonates For Multiple Myeloma Bone...
A group of leading myeloma specialists, known as the International Myeloma Working Group, recently collaborated to develop guidelines for the proper management of bone disease in multiple myeloma. The...
View ArticleMyeloma Research To Be Presented At The American Society of Clinical...
The 47th annual meeting of the American Society of Clinical Oncology (ASCO) will take place Friday, June 3, through Tuesday, June 7, in Chicago. More than 30,000 clinical specialists from all over the...
View ArticleRecent Advances In The Treatment Of Myeloma Bone Disease
Multiple myeloma is the most frequent cancer to involve the skeleton, with up to 80 percent of patients having bone disease. Although fewer patients appear to have bone involvement more recently, it is...
View ArticleLaser Surgery May Be An Effective Alternative For The Treatment Of Jawbone Death
Results of a small Turkish study indicate that laser surgery may be a viable treatment option for cancer patients who experience bisphosphonate-related bone death in their jaws. Specifically, the study...
View ArticleASCO 2012 Multiple Myeloma Update – Day Three: New Myeloma Treatments
Today was the third day of the American Society of Clinical Oncology (ASCO) annual meeting, and the morning was filled with oral presentations about important myeloma-related studies. Most of the...
View ArticleBeacon NewsFlashes – May 6, 2013
Daratumumab Receives Breakthrough Therapy Designation For Multiple Myeloma – The U.S. Food and Drug Administration (FDA) last week granted breakthrough therapy designation to the investigational drug...
View ArticleExperts Publish Treatment Recommendations For Multiple Myeloma-Related Bone...
The International Myeloma Working Group, a group of leading myeloma specialists, recently published its recommendations for the treatment of bone disease in multiple myeloma patients. The researchers...
View ArticleBeacon NewsFlashes – October 14, 2013
Patients With Periodontitis May Be At Increased Risk For Developing Osteonecrosis Of The Jaw – Results from a small Australian trial suggest that multiple myeloma patients who receive...
View Article
